P. Brisou (Spécialiste du service de santé des Armées) , J.-M. Chamouilli (Praticien hospitalier, chef de service de pédiatrie) , T. Gaillard (Assistante du service de santé des Armées) , Y. Muzellec (Spécialiste du service de santé des Armées)
{"title":"感染:肺炎","authors":"P. Brisou (Spécialiste du service de santé des Armées) , J.-M. Chamouilli (Praticien hospitalier, chef de service de pédiatrie) , T. Gaillard (Assistante du service de santé des Armées) , Y. Muzellec (Spécialiste du service de santé des Armées)","doi":"10.1016/j.emcped.2004.06.003","DOIUrl":null,"url":null,"abstract":"<div><p>Currently, pneumococcal infections are a public health problem. <em>Streptococcus pneumoniae</em> is a leading cause of community acquired invasive and non invasive bacterial infections in infants and young children, more specifically among those under five years. Pneumococcal invasive infections, in particular meningitis, carry a mortality upper than 8 % and a high risk of sequelae. Atypical clinical expression is frequent in youngest children. Membrane immunochromatography for rapid detection of urinary C-polysaccharide antigen is one of the advances for biological diagnosis, but it remains to be evaluated in children. Due to the increasing prevalence of penicillin-resistant pneumococci, treatment has to be adapted to clinical and epidemiological features. Frequent, serious, antibiotic-resistant characters of pneumococcal infections plea for vaccine. In France, Pneumo 23<sup>®</sup> indications were extended in 1998, and pneumococcal conjugate vaccine Prevenar<sup>®</sup> indications were modified in 2002. Local, national and international surveys are needed to adapt treatment and vaccine strategies.</p></div>","PeriodicalId":100441,"journal":{"name":"EMC - Pédiatrie","volume":"1 4","pages":"Pages 410-431"},"PeriodicalIF":0.0000,"publicationDate":"2004-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emcped.2004.06.003","citationCount":"5","resultStr":"{\"title\":\"Infections à pneumocoque\",\"authors\":\"P. Brisou (Spécialiste du service de santé des Armées) , J.-M. Chamouilli (Praticien hospitalier, chef de service de pédiatrie) , T. Gaillard (Assistante du service de santé des Armées) , Y. Muzellec (Spécialiste du service de santé des Armées)\",\"doi\":\"10.1016/j.emcped.2004.06.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Currently, pneumococcal infections are a public health problem. <em>Streptococcus pneumoniae</em> is a leading cause of community acquired invasive and non invasive bacterial infections in infants and young children, more specifically among those under five years. Pneumococcal invasive infections, in particular meningitis, carry a mortality upper than 8 % and a high risk of sequelae. Atypical clinical expression is frequent in youngest children. Membrane immunochromatography for rapid detection of urinary C-polysaccharide antigen is one of the advances for biological diagnosis, but it remains to be evaluated in children. Due to the increasing prevalence of penicillin-resistant pneumococci, treatment has to be adapted to clinical and epidemiological features. Frequent, serious, antibiotic-resistant characters of pneumococcal infections plea for vaccine. In France, Pneumo 23<sup>®</sup> indications were extended in 1998, and pneumococcal conjugate vaccine Prevenar<sup>®</sup> indications were modified in 2002. Local, national and international surveys are needed to adapt treatment and vaccine strategies.</p></div>\",\"PeriodicalId\":100441,\"journal\":{\"name\":\"EMC - Pédiatrie\",\"volume\":\"1 4\",\"pages\":\"Pages 410-431\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.emcped.2004.06.003\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMC - Pédiatrie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1762601304000394\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Pédiatrie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762601304000394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Currently, pneumococcal infections are a public health problem. Streptococcus pneumoniae is a leading cause of community acquired invasive and non invasive bacterial infections in infants and young children, more specifically among those under five years. Pneumococcal invasive infections, in particular meningitis, carry a mortality upper than 8 % and a high risk of sequelae. Atypical clinical expression is frequent in youngest children. Membrane immunochromatography for rapid detection of urinary C-polysaccharide antigen is one of the advances for biological diagnosis, but it remains to be evaluated in children. Due to the increasing prevalence of penicillin-resistant pneumococci, treatment has to be adapted to clinical and epidemiological features. Frequent, serious, antibiotic-resistant characters of pneumococcal infections plea for vaccine. In France, Pneumo 23® indications were extended in 1998, and pneumococcal conjugate vaccine Prevenar® indications were modified in 2002. Local, national and international surveys are needed to adapt treatment and vaccine strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
